The latest market report from GEN shows the top R&D spenders in the industry in 2012 as follows:
- Roche $10.1 B (up $1.3 B with restructuring costs)
- Novartis $9.3 B
- Merck $8.2 B
- Pfizer $7.9 B (down $1.2 B)
- J&J $7.7 B
- Sanofi $6.4 B
- GSK $5.95 B
- Lilly $5.3 B
- AZ $5.24 B
- AbbVie $4.3 B
Total spend for the group wwas $70.37 B in 2012 versus a slightly higher $70.38 B in 2011.
Posted by Bruce Lehr Mar 18th 2013.
Comments